natgillin/translations-raw huggingface dataset:
10 vials + 10 pre-filled syringes without needle
10 vial +10 napolnjenih brizg brez igle
20 vials + 20 pre-filled syringes without needle
20 vial +20 napolnjenih brizg brez igle
1 vial + 1 pre-filled syringe + 1 needle
1 viala + 1 napolnjena brizga + 1 igla
10 vials + 10 pre-filled syringes + 10 needles
10 vial +10 napolnjenih brizg + 10 igel
1 vial + 1 pre-filled syringe + 2 needles
1 viala +1 napolnjena brizga +2 igli
10 vials + 10 pre-filled syringes + 20 needles
10 vial +10 napolnjenih brizg +20 igel
20 vials + 20 pre-filled syringes + 20 needles
20 vial +20 napolnjenih brizg +20 igel
20 vials + 20 pre-filled syringes + 40 needles
20 vial +20 napolnjenih brizg +40 igel
Measles virus1 Enders’ Edmonston strain (live, attenuated)............ not less than 3.00 log10 TCID50* Mumps virus1 Jeryl Lynn™ (Level B) strain (live, attenuated)....... not less than 4.30 log10 TCID50 Rubella virus2 Wistar RA 27/ 3 strain (live, attenuated)................... not less than 3.00 log10 TCID50 Varicella virus3 Oka/ Merck strain (live, attenuated)........................ not less than 3.99 log10 PFU**
Virus ošpic1, sev Enders ’ Edmonston (živ, oslabljen) najmanj 3, 00 log10 TCID50 * Virus mumpsa1, sev Jeryl Lynn™ (nivo B) (živ, oslabljen) najmanj 4, 30 log10 TCID50 Virus rdečk2, sev Wistar RA 27/ 3 (živ, oslabljen) najmanj 3, 00 log10 TCID50 Virus varicella- zoster3, sev Oka/ Merck (živ, oslabljen) najmanj 3, 99 log10 PFU **
2/ 2 * 50% tissue culture infectious dose ** plaque-forming units
* 50% - na infektivna doza na tkivni kulturi (TCID = tissue culture infectious dose) ** enote, ki tvorijo plak (PFU = plaque- forming units)
(1) Produced in chick embryo cells.
(1) Pridobljen iz celic piščančjih zarodkov.
(2) Produced in human diploid lung (WI-38) fibroblasts.
(2) Pridobljen iz človeških diploidnih pljučnih (WI- 38) fibroblastov.
(3) Produced in human diploid (MRC-5) cells.
(3) Pridobljen iz človeških diploidnih (MRC- 5) celic.
Measles, mumps, rubella and varicella vaccine (live).
ProQuad prašek in vehikel za suspenzijo za injiciranje cepivo proti ošpicam, mumpsu, rdečkam in noricam (živo).
Measles virus1 Enders’ Edmonston strain (live, attenuated)........ not less than 3.00 log10 CCID50* Mumps virus1 Jeryl Lynn™ (Level B) strain (live, attenuated).. not less than 4.30 log10 CCID50* Rubella virus2 Wistar RA 27/ 3 strain (live, attenuated).............. not less than 3.00 log10 CCID50* Varicella virus3 Oka/ Merck strain (live, attenuated)................... not less than 3.99 log10 PFU**
Virus ošpic1, sev Enders ’ Edmonston (živ, oslabljen).......................... najmanj 3, 00 log10 CCID50 * Virus mumpsa1, sev Jeryl Lynn™ (nivo B) (živ, oslabljen)................. najmanj 4, 30 log10 CCID50 * Virus rdečk2, sev Wistar RA 27/ 3 (živ, oslabljen)................................ najmanj 3, 00 log10 CCID50 * Virus varicella- zoster3, sev Oka/ Merck (živ, oslabljen)....................... najmanj 3, 99 log10 PFU **
*50% cell culture infectious dose **plaque-forming units
* 50- odstotni infektivni odmerek na celični kulturi (CCID = cell culture infectious dose) ** enote, ki tvorijo plak (PFU = plaque- forming units)
Powder and solvent for suspension for injection.
Prašek in vehikel za suspenzijo za injiciranje.
Before reconstitution, the powder is a white to pale yellow compact crystalline cake and the solvent is a clear colourless liquid.
Pred pripravo je prašek bel do bledo rumen kompakten kristalni skupek, vehikel pa je bistra, brezbarvna tekočina.
Posology Individuals from 12 months of age should receive two doses of ProQuad or a single dose of ProQuad followed by a second dose of a monovalent varicella vaccine to ensure optimal protection against varicella (see section 5.1).
Odmerjanje Pri posameznikih, starih od 12 mesecev dalje, sta za zagotovitev optimalne zaščite proti noricam potrebna dva odmerka cepiva ProQuad ali en odmerek cepiva ProQuad in za njim drugi odmerek enovalentnega cepiva proti noricam (glejte poglavje 5. 1).
At least one month must elapse between the first and second dose of any live viral attenuated vaccine.
Med prvim in drugim odmerkom kateregakoli cepiva z oslabljenim živim virusom, vključno s cepivom ProQuad, mora miniti vsaj en mesec.
Note: applicable official recommendations may vary regarding the interval between doses and the need for two or one doses of measles, mumps and rubella and of varicella-containing vaccine.
Opomba: ustrezna uradna priporočila se lahko razlikujejo glede na interval med odmerkoma in potrebnost cepljenja z dvema odmerkoma ali enim odmerkom cepiva proti ošpicam, mumpsu in rdečkam, ter cepiva, ki vsebuje virus noric.
ProQuad may be used as the second dose in individuals from 12 months of age who have previously received measles, mumps, and rubella vaccine and varicella vaccine.
Cepivo ProQuad lahko uporabimo kot drugi odmerek cepljenja v starosti od 12 mesecev dalje pri posameznikih, ki so bili že cepljeni s cepivom proti ošpicam, mumpsu in rdečkam in cepivom proti noricam.
2 Method of administration The vaccine is to be injected by the subcutaneous route in the deltoid region of the upper arm or in the higher anterolateral area of the thigh.
2 Način uporabe Cepivo je treba injicirati pod kožo (subkutano) v področje deltoidne mišice nadlahti ali v zgornje anterolateralno področje stegna.
History of hypersensitivity to any varicella vaccine or measles, mumps, or rubella vaccine, to any of the excipients, or to neomycin, which may be present as trace residues (see sections 2, 4.4 and 6.1).
Preobčutljivost v preteklosti za katerokoli cepivo z virusom noric ali cepivo proti ošpicam, mumpsu ali rdečkam, za katerokoli pomožno snov ali za neomicin, ki je lahko prisoten v sledeh (glejte poglavja 2, 4. 4 in 6. 1).
Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system.
Krvne diskrazije, levkemija, katerakoli vrsta limfoma ali druga maligna novotvorba, ki vpliva na hematopoetski in limfatični sistem.
ProQuad is not contraindicated in individuals who are receiving topical or low-dose parenteral corticosteroids (e. g. for asthma prophylaxis or replacement therapy).
Cepivo ProQuad ni kontraindicirano pri osebah, ki dobivajo topične ali majhne parenteralne odmerke kortikosteroidov (npr. kot profilakso astme ali kot nadomestno zdravljenje).
Humoral or cellular (primary or acquired) immunodeficiency, including hypogammaglobulinemia and dysgammaglobulinemia and AIDS, or symptomatic HIV infection or a CDC Class 2 or higher or an age-specific CD4+ T-lymphocyte percentage < 25% (see section 4.4).
Humoralna ali celična (primarna ali pridobljena) imunska pomankljivost, vključno s hipogamaglobulinemijo, disgamaglobulinemijo in AIDS- om, simptomatska okužba z virusom HIV ali CDC razred 2 ali višji ali starostno specifični odstotek CD4+ T- limfocitov < 25% (glejte poglavje 4. 4).
In severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported.
Pri hudo imunsko oslabljenih osebah, ki so jih pomotoma cepili s cepivom proti ošpicam, so poročali o ošpičnem encefalitistu z inkluzijskimi telesci, pnevmonitisu in smrti kot neposredni posledici razsejane okužbe s cepilnim virusom ošpic.
Pregnancy (see also sections 4.4 and 4.6).
Nosečnost (glejte poglavji 4. 4 in 4. 6).
Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e. g. hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions.
Osebe z anamnezo anafilaktične, anafilaktoidne ali druge takojšnje reakcije (npr. koprivnica, oteklina ust in grla, težave pri dihanju, hipotenzija ali šok) po zaužitju jajc imajo lahko večje tveganje takojšnjih preobčutljivostnih reakcij.
The potential risk- to-benefit ratio should be carefully evaluated before considering vaccination in such cases.
V takih primerih je treba skrbno oceniti morebitno tveganje in korist, preden bi se odločili za cepljenje.
The physician should be alert to the temperature elevation that may occur following vaccination (see section 4.8).
Zdravnik mora biti pozoren na morebiten porast temperature po cepljenju (glejte poglavje 4. 8).
This vaccine contains 16 mg of sorbitol as an excipient.
To cepivo vsebuje 16 mg pomožne snovi sorbitola.
Patients with rare hereditary problems of fructose intolerance should not take this vaccine.
Bolniki z redko dedno intoleranco za fruktozo ne smejo jemati tega cepiva.
3 Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with ProQuad as Reye's syndrome has been reported following the use of salicylates during wild-type varicella infection.
3 Prejemniki cepiva se morajo 6 tednov po cepljenju s cepivom ProQuad izogibati jemanju salicilatov, saj so pri uporabi salicilatov med okužbo z divjim sevom noric poročali o Reyevem sindromu.
As for any vaccine, vaccination with ProQuad may not result in protection in all vaccine recipients.
Kot pri drugih cepivih, tudi pri cepljenju s cepivom ProQuad, zaščita vseh cepljenih posameznikov lahko ni popolna.
Pregnancy See sections 4.3 and 4.6.
Nosečnost Glejte poglavji 4. 3 in 4. 6.
Transmission Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination.
Prenos Pri večini cepljenih, za rdečke dovzetnih posameznikov je 7 do 28 dni po cepljenju prišlo do izločanja majhnih količin živega oslabljenega virusa rdečk iz nosu ali grla.
Consequently, transmission through close personal contact, while accepted as a theoretical possibility, is not regarded as a significant risk; however, transmission of the rubella vaccine virus to infants via breast milk has been documented without any evidence of clinical disease (see section 4.6).
Zato se prenos s tesnim osebnim stikom, ki je teoretično možen, ne smatra za pomembno tveganje; dokumentirali pa so prenos cepilnega virusa rdečk na dojenčka z materinim mlekom, brez kliničnih znakov bolezni (glejte poglavje 4. 6).
There are no reports of transmission of the more attenuated Enders’ Edmonston strain of measles virus or the Jeryl Lynn ™ strain of mumps virus from vaccine recipients to susceptible contacts.
Ni poročil o prenosu bolj oslabljenega seva Enders 'Edmonston virusa ošpic ali seva Jeryl Lynn™ virusa mumpsa s cepljenih oseb na kontaktne osebe, dovzetne za okužbo z virusom ošpic in mumpsa.
Post-licensing experience with Varicella Vaccine live (Oka/ Merck) suggests that transmission of varicella vaccine virus may rarely occur between healthy vaccine recipients who develop a varicella- like rash and contacts susceptible to varicella, as well as high-risk individuals susceptible to varicella (see section 4.8).
Izkušnje s tržišča s cepivom z živim virusom noric (Oka/ Merck) kažejo, da lahko redko pride do prenosa cepilnega virusa noric z zdravih cepljenih oseb, pri katerih se pojavi noricam podoben izpuščaj, na kontaktne osebe, sprejemljive za norice, pa tudi na osebe z velikim tveganjem, sprejemljive za norice (glejte poglavje 4. 8).
• immunocompromised individuals (see section 4.3), • pregnant women without documented positive history of varicella (chickenpox) or laboratory evidence of prior infection, • newborn infants of mothers without documented positive history of varicella or laboratory evidence of prior infection.
• osebe s pomanjkljivo imunostjo (glejte poglavje 4. 3), • nosečnice brez dokumentirane prejšnje okužbe z noricami (varičelo) ali laboratorijskega dokaza prebolele okužbe, • novorojenčki mater brez dokumentirane prejšnje okužbe z noricami ali laboratorijskega dokaza prebolele okužbe.
Thrombocytopenia No clinical data are available regarding the development or worsening of thrombocytopenia in individuals vaccinated with ProQuad.
Trombocitopenija Ni kliničnih podatkov o pojavu ali poslabšanju trombocitopenije pri osebah, cepljenih s cepivom ProQuad.
However, post-marketing experience with live measles, mumps, and rubella vaccine indicates that individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination.
Vendar pa izkušnje s tržišča z živim cepivom proti ošpicam, mumpsu in rdečkam kažejo, da se lahko pri osebah s trombocitopenijo le- ta po cepljenju poslabša.
In addition, individuals who experienced thrombocytopenia following the first dose of a live measles, mumps, and rubella vaccine may develop thrombocytopenia with repeat doses.
Poleg tega se lahko pri osebah, pri katerih se je trombocitopenija pojavila po prvem cepljenju z živim cepivom proti ošpicam, mumpsu in rdečkam, trombocitopenija lahko pojavi po ponovnem odmerku.
The potential risk-to-benefit ratio should be carefully evaluated before considering vaccination with ProQuad in such cases (see section 4.8).
V takih primerih je treba skrbno pretehtati razmerje med morebitnim tveganjem in koristjo, preden se odločimo za cepljenje s cepivom ProQuad (glejte poglavje 4. 8).
Other No clinical data are available for ProQuad in individuals who are known to be infected with human immunodeficiency viruses without evidence of immunosuppression.
Drugo Kliničnih podatkov o cepivu ProQuad pri osebah z znano okužbo s človeškim virusom imunske pomanjkljivosti brez znakov zavore imunosti ni.
Careful risk-to-benefit evaluation should be done for these subjects (see section 4.3).
Pri teh osebah je treba skrbno pretehtati tveganje glede na korist (glejte poglavje 4. 3).
Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine.
Pri otrocih, ki se zdravijo zaradi tuberkuloze, ni prišlo do poslabšanja bolezni po cepljenju z živim cepivom proti virusu ošpic.
No studies have been reported to date on the effect of measles virus vaccines on children with untreated tuberculosis (see section 4.3).
Doslej ni bilo študij o vplivu cepiv proti ošpicam na otroke z nezdravljeno tuberkulozo (glejte poglavje 4. 3).
4 Post-exposure prophylaxis No clinical data are available for ProQuad administered after exposure to measles, mumps, rubella, or varicella.
4 Profilaksa po izpostavitvi Ni kliničnih podatkov o cepljenju s cepivom ProQuad po izpostavitvi ošpicam, mumpsu, rdečkam ali noricam.
However, post-exposure prophylaxis for varicella and measles has been demonstrated with Varicella Vaccine live (Oka/ Merck) and the measles-containing vaccines manufactured by Merck & Co., Inc., respectively.
Dokazana pa je bila profilaksa s cepivom z živim virusom noric (Oka/ Merck) po izpostavitvi noricam ter profilaksa s cepivi, ki vsebujejo cepivo proti ošpicam izdelovalca Merck & Co., Inc., po izpostavitvi ošpicam.
At least 1 month should elapse between receipt of a live virus vaccine and ProQuad.
Med cepljenjem z živim virusnim cepivom in cepljenjem s cepivom ProQuad mora miniti najmanj en mesec.
Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with ProQuad (see section 4.4).
Prejemniki cepiva naj se vsaj 6 tednov po cepljenju s cepivom ProQuad izogibajo uporabi salicilatov (glejte poglavje 4. 4).
Do not give immunoglobulin (IG) or Varicella Zoster Immune Globulin (VZIG) concomitantly with ProQuad.
Sočasno s cepivom ProQuad ne dajajte imunoglobulinov (IG) ali Varicella- Zoster imunoglobulina (VZIG).
However, the appropriate suggested interval between transfusion or IG administration and vaccination will vary with the type of transfusion or indication for, and dose of, IG (e. g.
Ustrezni priporočeni presledek med transfuzijo ali prejemom IG ter cepljenjem se razlikuje glede na vrsto transfuzije ali indikacijo in odmerek IG (npr.
Administration of varicella zoster virus antibody-containing blood products, including VZIG or other immune globulin preparations, within 1 month following a dose of ProQuad may reduce the immune response to the vaccine and hence reduce its protective efficacy.
Če cepljena oseba v 1 mesecu po cepljenju s cepivom ProQuad dobi krvne pripravke, ki vsebujejo VZIG ali druge pripravke imunoglobulinov, lahko to oslabi imunski odziv na cepljenje in zmanjša učinkovitost njegove zaščite.
Therefore, administration of any of these products should be avoided within 1 month after a dose of ProQuad unless considered to be essential.
Zato se je treba 1 mesec po cepljenju s cepivom ProQuad izogibati dajanju kateregakoli od teh pripravkov, razen če je nujno potrebno.
It has been reported that live attenuated measles, mumps and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity.
Opisano je bilo, da lahko cepljenje s posameznimi oslabljenimi živimi cepivi proti ošpicam, mumpsu in rdečkam začasno zmanjša kožno občutljivost na tuberkulin.
Therefore, if a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 to 6 weeks after immunization with ProQuad.
Če načrtujete tuberkulinski test, ga je treba opraviti kadarkoli pred cepljenjem s cepivom ProQuad, hkrati z njim ali vsaj 4 do 6 tednov po njem.
There are insufficient data to support the use of ProQuad with any other vaccines.
Ni dovolj podatkov v podporo uporabi cepiva ProQuad s katerimkoli drugim cepivom.
Studies have not been conducted with ProQuad in pregnant women.
Študij o cepljenju s cepivom ProQuad pri nosečnicah ni bilo.
Therefore, ProQuad should not be administered to pregnant females; furthermore, pregnancy should be avoided for 3 months following vaccination (see sections 4.1, 4.3 and 4.4).
Zato s cepivom ProQuad ne smemo cepiti nosečnic, poleg tega je 3 mesece po cepljenju potrebna uporaba učinkovite kontracepcije (glejte poglavja 4. 1, 4. 3 in 4. 4).
In order to advise women who are inadvertently vaccinated when pregnant or who become pregnant within 3 months after vaccination, the physician should be aware of the following:
Pri svetovanju ženskam, ki so pomotoma cepljene v nosečnosti ali ki zanosijo v 3 mesecih po cepljenju, se mora zdravnik zavedati naslednjih dejstev:
(1) Reports have indicated that contracting of wild-type measles during pregnancy enhances foetal risk.
(1) Poročila so pokazala, da okužba z divjim sevom ošpic med nosečnostjo poveča tveganje za plod.
Increased rates of spontaneous abortion, stillbirth, congenital defects and prematurity have been observed subsequent to wild-type measles during pregnancy.
Po okužbi z divjim sevom ošpic med nosečnostjo so ugotovili večji delež spontanih splavov, mrtvorojenosti, prirojenih napak in prezgodnjih porodov.
There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy.
Ustreznih študij o oslabljenem (cepilnem) sevu virusa ošpic v nosečnosti ni.
However, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse foetal effects; (2) Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion.
Razumno pa bi bilo predvidevati, da lahko tudi cepilni sev virusa škodljivo vpliva na plod; (2) Okužba z mumpsom v prvem trimesečju nosečnosti lahko poveča delež spontanih splavov.
Although mumps vaccine virus has been shown to infect the placenta and foetus, there is no evidence that it causes congenital malformations in humans; (3) In a 15-year survey involving over 1100 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 635 received the Wistar RA 27/ 3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome; and (4) Wild-type varicella is known to cause foetal harm, and is associated with an increased risk of herpes zoster in the first year of life and severe varicella in the newborn infant.
Čeprav so za virus mumpsa dokazali, da okuži posteljico in plod, ni dokazov, da pri ljudeh povzroča prirojene napake; (3) V 15- letni študiji več kot 1100 nosečnic, ki so bile 3 mesece pred zanositvijo ali po njej cepljene proti rdečkam (med njimi jih je bilo 635 cepljenih s sevom Wistar RA 27/ 3), ni imel noben novorojenček prirojenih okvar, ki bi ustrezale sindromu prirojenih rdečk; ter (4) Znano je, da okužba z divjim sevom noric škoduje plodu in je povezana z večjim tveganjem pasavca v prvem letu življenja ter hudimi noricami novorojenčka.
5 Note: official recommendations may vary regarding the duration of the waiting period that is recommended for avoiding pregnancy following vaccination.
Opomba: uradna priporočila lahko navajajo različna obdobja, ko se je po cepljenju treba izogibati nosečnosti.
Studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants.
5 Študije so pokazale, da lahko doječe matere, ki so bile po porodu cepljene z živim oslabljenim cepivom proti rdečkam, izločajo virus v mleku in ga prenesejo na dojenčke.
It is not known whether measles or mumps vaccine virus is secreted in human milk.
Ni znano, ali se cepilni virus ošpic ali mumpsa izloča v materinem mleku.
No studies on the affects on the ability to drive or use machinery have been performed.
Študij o vplivu na sposobnost vožnje in upravljanja s stroji niso izvedli.
In 5 clinical trials, ProQuad was administered without concomitant vaccines to 6038 children 12 through 23 months of age.
V 5- ih kliničnih študijah je bilo s cepivom ProQuad brez sočasnega dodatka drugih cepiv cepljenih 6038 otrok, starih 12 do 23 mesecev.
The children in these studies received either the current refrigerator-stable formulation or an earlier formulation of ProQuad.
Otroci so v teh študijah prejeli bodisi obstoječo obliko cepiva stabilnega v hladilniku ali predhodno obliko cepiva ProQuad.
Children in these studies were monitored for six weeks post vaccination.
Otroke so v teh študijah spremljali do 6 tednov po cepljenju.
The safety profiles were comparable for the two different formulations after a single dose.
Varnost obeh različnih oblik cepiva je bila po enkratnem odmerku primerljiva.
The only vaccine-related systemic adverse reactions reported at a significantly greater rate in individuals who received the earlier formulation of ProQuad compared to individuals who received the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc. and Varicella Vaccine live (Oka/ Merck) were fever (≥ 38.9°C oral equivalent or abnormal) and measles-like rash.
Edina s cepljenjem povezana sistemska neželena učinka, o katerih so značilno pogosteje poročali pri otrocih, ki so dobili predhodno obliko cepiva ProQuad, v primerjavi s posamezniki, ki so prejeli cepivo proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc in cepivo z živim virusom noric (Oka/ Merck), sta bila zvišana telesna temperatura (≥ 38, 9 °C merjeno v ustih ali nenormalna) ter ošpicam podoben izpuščaj.
Pain/ tenderness/ soreness at the injection site was reported at a statistically lower rate in individuals who received ProQuad.
O bolečini/ občutljivosti/ bolečnosti na mestu injiciranja so statistično redkeje poročali pri otrocih, ki so bili cepljeni s cepivom ProQuad.
Inc. was rash at the injection site.
Edini s cepljenjem povezan neželen učinek, ki je bil pri prejemnikih cepiva ProQuad pogostejši kot pri prejemnikih cepiva z živim virusom noric (Oka/ Merck) in cepiva proti ošpicam, mumpsu in rdečkam izdelovalca Merck & Co., Inc., je bil izpuščaj na mestu injiciranja.
Children who received a second dose of ProQuad The rates of adverse reactions after a second dose of ProQuad were generally similar to, or lower than, those seen with the first dose.
Otroci, ki so bili cepljeni z drugim odmerkom cepiva ProQuad Deleži neželenih učinkov po drugem odmerku cepiva ProQuad so bili na splošno podobni ali manjši od tistih po prvem cepljenju.
The fever rate was lower after the second dose than after the first dose (see section 5.1 for study description).
Delež zvišane telesne temperature je bil po drugem cepljenju manjši kot po prvem (glejte poglavje 5. 1 za opis študije).